A major product-liability storm is building around Medtronic and its subsidiary Given Imaging following a sweeping global voluntary recall of the Bravo CF esophageal pH-monitoring capsule delivery device. With 184 serious injuries already documented, a Class I FDA recall classification issued on September 15, 2026, and major plaintiffs’ firms now accepting cases nationwide, the Medtronic Bravo CF capsule lawsuit is shaping up to be one of the most consequential emerging medical device litigations of 2026. If you or a loved one underwent an esophageal pH monitoring procedure using a Bravo CF device, here is everything you need to know right now.
What Is the Medtronic Bravo CF Device and Why Was It Recalled?
The Bravo CF Capsule Delivery Device is a medical tool used during esophageal pH monitoring procedures to diagnose gastroesophageal reflux disease (GERD) and related acid reflux conditions. During the procedure, a small pH-sensing capsule is attached to the wall of the esophagus using the delivery device, where it records acid levels over 48 to 96 hours before naturally detaching and passing through the digestive system.
In August 2026, Medtronic and Given Imaging initiated a global voluntary recall after reports of serious patient injuries began accumulating at an alarming rate. According to reporting by MassDevice on August 31, 2026, the recall was triggered by a deployment control defect linked to 184 serious injuries. The root cause, as identified in Medtronic’s preliminary investigation, involves the misapplication of adhesive during the manufacturing process. This defect may prevent the capsule from attaching properly to the esophagus — or, just as dangerously, may cause the capsule to detach from the delivery device prematurely during placement inside the patient’s body.
The affected products are the Bravo CF Capsule Delivery Device 5-pack (model FGS-0635) and 1-pack (model FGS-0636), covering units with expiration dates on or before October 20, 2027. Hospitals and endoscopy centers were instructed to immediately identify and quarantine affected devices from listed lots and return unused products to Medtronic for replacement. To understand how injuries from defective medical devices are legally valued, victims can reference a medical malpractice calculator as an early benchmarking tool.
FDA Class I Recall: The Highest Severity Classification
The FDA’s response to this crisis has been unambiguous and urgent. On August 27, 2026, the agency issued an Early Alert — a designation reserved for situations demanding immediate public notification before a full recall notice can be finalized. That Early Alert was followed by a formal Class I recall classification on September 15, 2026, as reported by HPN Online on September 16, 2026. A Class I recall is the FDA’s most serious category, indicating a reasonable probability that use of the product will cause serious adverse health consequences or death.
According to FDA guidelines available through the U.S. Food and Drug Administration, a Class I classification is not issued lightly. It signals that the agency has concluded the risk to patients is not theoretical — it is demonstrated and ongoing. The Bravo CF recall joining this tier places Medtronic under intense regulatory scrutiny and significantly strengthens the legal foundation for injured patients filing product-liability claims.
Critically, this is not Medtronic’s first warning about this specific failure mode. In June 2025, the company issued a narrower, earlier recall covering a subset of affected lots. That prior recall places Medtronic on notice — a legal concept meaning the company had reason to know about the defect and had a heightened duty to correct it. Plaintiffs’ attorneys are already citing the June 2025 recall as evidence of corporate knowledge in the emerging Medtronic Bravo CF capsule lawsuit filings.
Serious Injuries Reported: What Patients Faced
The human cost of the Bravo CF defect is severe. According to data compiled from recall notices and injury reports, the risks associated with a malfunctioning capsule delivery device include some of the most dangerous complications possible during a gastrointestinal procedure. These documented risks include:
- Aspiration and inhalation of the capsule or device components into the airway
- Obstruction of the airway, creating an immediately life-threatening emergency
- Perforation of the esophagus, which can lead to mediastinitis and sepsis
- Laceration of the esophagus from an improperly deployed or detached capsule
- Hemorrhage and significant blood loss
- Retained foreign bodies remaining inside the patient after the procedure
- Delayed diagnosis of GERD or other conditions due to device malfunction
- Infection and sepsis resulting from esophageal trauma or retained device components
As of August 10, 2026, no deaths had been reported in connection with the recall, according to HPN Online. However, given the severity of risks including airway obstruction and esophageal perforation, the potential for a fatality is recognized by both regulators and legal experts monitoring the Medtronic Bravo CF capsule lawsuit landscape. Families who have lost a loved one following such a procedure should consult a wrongful death calculator to begin understanding the full scope of recoverable damages.
Recall Data at a Glance
| Recall Detail | Information | Source / Date |
|---|---|---|
| Initiating Companies | Medtronic / Given Imaging | MassDevice, Aug. 31, 2026 |
| FDA Early Alert Issued | August 27, 2026 | HPN Online, Sept. 16, 2026 |
| FDA Class I Classification | September 15, 2026 | HPN Online, Sept. 16, 2026 |
| Total Serious Injuries Reported | 184 (as of August 10, 2026) | MassDevice / yourlawyer.com, 2026 |
| Deaths Reported | None confirmed as of Aug. 10, 2026 | HPN Online, Sept. 16, 2026 |
| Affected Models | FGS-0635 (5-pack), FGS-0636 (1-pack) | HPN Online, Sept. 16, 2026 |
| Affected Expiration Range | On or before October 20, 2027 | HPN Online, Sept. 16, 2026 |
| Prior Related Recall | June 2025 (subset of lots) | MDDI Online / Weitz & Luxenberg, 2026 |
| Root Cause | Adhesive misapplication during manufacturing | Cory Watson Attorneys, 2026 |
| MDL Status | No MDL formed as of October 22, 2026 | Mass Tort Injury Calculator, Oct. 2026 |
Litigation Update: Law Firms Filing Cases and What Comes Next
The legal response to the Bravo CF recall has been swift. Weitz & Luxenberg, one of the nation’s most prominent mass tort firms, began accepting cases as early as September 3, 2026 — less than one week after the FDA’s Early Alert — describing the device as “potentially very dangerous.” Cory Watson Attorneys announced they are actively investigating claims for patients who suffered aspiration, esophageal perforation, airway obstruction, bleeding, retained foreign objects, infection and sepsis, and harm from delayed diagnosis.
On October 15, 2026, Drugwatch identified the Medtronic Bravo CF capsule lawsuit as one of the most significant emerging device litigations of the year — a designation that signals the legal community’s expectation that the case volume will grow substantially. Individual product-liability and wrongful death cases are currently being filed in state and federal courts across the country.
As of October 22, 2026, no Multidistrict Litigation (MDL) has been formed. Under 28 U.S.C. § 1407, the Judicial Panel on Multidistrict Litigation can consolidate federal cases sharing common questions of fact into a single district court for pretrial proceedings. The absence of an MDL at this stage is notable — it means victims who file now may benefit from earlier case resolution, more individualized attention from counsel, and potentially stronger leverage in early settlement negotiations before litigation becomes heavily consolidated and standardized.
For individuals seeking to understand the potential value of their Medtronic Bravo CF capsule lawsuit claim before speaking with an attorney, a personal injury settlement calculator can provide a preliminary framework based on injury type, medical costs, and other documented losses.
Who May Have a Valid Claim
You may be eligible to join a Medtronic Bravo CF capsule lawsuit if you or a family member underwent an esophageal pH monitoring procedure using a Bravo CF capsule delivery device — particularly between the June 2025 narrower recall and the August 2026 full global recall — and experienced one or more of the following outcomes:
- Aspiration or inhalation of any device component during or after the procedure
- Esophageal perforation, laceration, or rupture
- Airway obstruction requiring emergency intervention
- Uncontrolled bleeding or hemorrhage
- A retained foreign body identified on imaging after the procedure
- Infection, sepsis, or mediastinitis following the procedure
- A failed or delayed GERD diagnosis due to device malfunction
- Hospitalization, additional surgery, or prolonged recovery directly tied to a Bravo CF procedure
Product-liability claims in medical device cases can pursue compensation for medical expenses, lost income, pain and suffering, permanent disability, and in cases of wrongful death, funeral costs and loss of financial support. Applicable legal standards vary by state, and statutes of limitations — the deadlines by which lawsuits must be filed — differ significantly across jurisdictions. Relevant standards for product-liability claims are addressed under Justia’s product liability resources, which outline the general theories of negligence, strict liability, and breach of warranty applicable in these cases.
Frequently Asked Questions About the Medtronic Bravo CF Capsule Lawsuit
What is the Medtronic Bravo CF capsule recall about?
Medtronic and its subsidiary Given Imaging issued a global voluntary recall of the Bravo CF Capsule Delivery Device (models FGS-0635 and FGS-0636) in August 2026 after 184 serious injuries were linked to a manufacturing defect involving misapplication of adhesive. The defect can cause the pH-sensing capsule to fail to attach to the esophagus or to detach from the delivery device mid-procedure, creating risks of airway obstruction, esophageal perforation, hemorrhage, and retained foreign bodies. The FDA issued an Early Alert on August 27, 2026, and assigned a Class I recall classification — its most serious level — on September 15, 2026.
Who qualifies to file a Medtronic Bravo CF capsule lawsuit?
Patients who underwent an esophageal pH monitoring procedure using a recalled Bravo CF delivery device and suffered injuries such as aspiration, esophageal perforation, airway obstruction, bleeding, retained foreign bodies, or sepsis may qualify to file a claim. Family members of patients who died following such a procedure may be eligible to file a wrongful death lawsuit. The key factors are: the device used falls within the recalled lot numbers and expiration range, and the patient suffered a documented injury tied to device malfunction.
Has an MDL been formed for Bravo CF capsule lawsuits?
As of October 22, 2026, no Multidistrict Litigation (MDL) has been formed for Medtronic Bravo CF capsule lawsuits. Cases are currently being filed individually in state and federal courts across the country. The absence of an MDL means this litigation is still in an early, fragmented stage — which may create advantages for plaintiffs who act quickly, including more individualized case handling and earlier potential resolution before the litigation landscape consolidates.
What injuries are being investigated in Bravo CF capsule lawsuits?
Attorneys investigating the Medtronic Bravo CF capsule lawsuit are specifically pursuing claims on behalf of patients who suffered aspiration or inhalation of capsule components, esophageal perforation or laceration, airway obstruction, hemorrhage, retained foreign objects inside the body, infection or sepsis, and harm from delayed GERD diagnosis caused by device failure. These injuries range in severity from requiring emergency intervention to causing long-term disability. As of August 10, 2026, no deaths had been confirmed, but the severity of documented risks makes wrongful death claims a foreseeable future category.
Did Medtronic have prior warning about the Bravo CF defect?
Yes. In June 2025 — more than a year before the August 2026 global recall — Medtronic issued a narrower recall covering a subset of Bravo CF device lots for a related issue. This prior recall is central to the legal theory that Medtronic had advance notice of the defect and a heightened obligation to correct it across all affected products. Plaintiffs’ attorneys describe this prior recall as establishing corporate knowledge, which can support claims of negligence and may be relevant to punitive damages arguments in the Medtronic Bravo CF capsule lawsuit.
Legal Disclaimer: The information provided on this page is for general informational purposes only and does not constitute legal advice, create an attorney-client relationship, or substitute for consultation with a qualified attorney licensed in your jurisdiction.
Related reading: Physician Assistant Malpractice Settlement Amounts: 2026 Data, Verdicts & How Compensation Is Calculated
Related reading: Affidavit Of Merit In Medical Malpractice: State Rules, Federal Court Exceptions & What The 2026 Supreme Court Ruling Means For Your Case
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.